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Abstract
Background: Former prospective analyses revealed gross tumor volume (GTV) as the most reliable parameter to
statistically significantly predict disease control in head neck cancer (HNC) patients treated with definitive intensity
modulated radiation therapy (IMRT) +/-concomitant systemic therapy. The most ‘unfavourable’ subgroup was
characterized by total GTV (tGTV) of > 70 cc, translating in ~50 and 65% 3-year disease free (DFS) and overall
survival (OAS, vs 68% and 88% in tGTV < 70 cc, p = 0.001 and 0.0001), and ~25% distant spread (vs 6% for tGTV <
70 cc, p < 0.0001).
The aim of this report was to analyze whether there is a subgroup out of patients with tGTV > 70 cc, which only
marginally benefits from intensive curative treatment.
Results: Between 03/2002-03/2011, 112 HNC patients with tGTV > 70 cc were definitively irradiated with curative
intention. Mean tGTV was 104 cc (71-251). 98/112 (88%) patients underwent systemic therapy. Parameters with
potential impact on disease outcome were retrospectively tested. The 3-year local-regional control (LRC), DFS and
OAS rates were 61%, 50%, and 58%. The used cut-off value of 130 cc revealed an inverse association between tGTV
and outcome. Patients able to undergo any systemic therapy (n = 98, mean tGTV0 103 cc, mean age 60 years)
showed a satisfying and significantly superior outcome compared to the subgroup with radiation alone (n = 14,
mean tGTV 99 cc, mean age 73 years), with 53% vs 17% 3-year DFS (p = 0.01). Radiation alone for tGTV > 130 cc
failed to aim its curative goal in 3/3 patients.
Conclusion: Patients with tGTV > 70 cc unable to undergo any systemic therapy represented a subgroup in which
disease control was achievable in < 20% following curatively intended IMRT. Prospective testing of a larger sample
size is needed to evaluate, if radiation alone for tGTV >~130 cc fails to meet its curative aim.
Keywords: loco-regionally advanced HNC, tumour volume as prognostic factor, systemic therapy in advanced HNC,
IMRT in advanced HNC
Background
Former analyses revealed gross tumor volume (GTV) as
the most reliable prognostic parameter for outcome in
head and neck cancer (HNC) patients treated with
simultaneous integrated boost intensity modulated
radiation therapy (SIB-IMRT) +/- concomitant systemic
therapy [1]: the ‘unfavourable’ subgroup was character-
ized by total GTV (tGTV) of > 70 cc, translating in ~50
and 65% 3-year disease free (DFS) and overall survival
(OAS, vs 68% and 88% for tGTV < 70 cc, p = 0.001/
0.0001), with distant spread in ~25% (vs 6% if tGTV <
70 cc, p < 0.0001) [2].
This ‘unfavourable’ subgroup represents one quarter of
all squamous cell carcinoma (SCC) HNC patients
referred to our institution for definitively IMRT in cura-
tive intention (112/458 (23%), 03/2011). Many patients
presenting with such advanced tumours are suffering
form alcohol abuse with related co-morbidities and fre-
quently limited compliance. For this cohort with consid-
erable risk for treatment failure and tolerance problems,
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the risk-benefit ratio of intensive treatment approaches
with curative intention remains difficult to estimate in
advance. Our philosophy is to try to prevent patients
from usually quickly developing severe loco-regional
symptoms due to large tumor volumes.
The aim of this report was to analyze whether there is
a subgroup identifiable which only marginally benefits
from intensive curative treatment.
Between March 2002 and March 2011, 112 HNC
patients with tGTV > 70 cc were treated using a pro-
spectively defined curative radiation therapy schedule.
Patients diagnosed with other than squamous cell carci-
noma or with nasopharyngeal cancer were excluded (n
= 24). In 98/112 patients (88%), systemic therapy was
administered. Table 1 shows patient and tumour charac-
teristic. A second (n = 24), third (n = 2) or even fourth
(n = 1) malignancy was diagnosed prior or after comple-
tion of treatment of the HNC in 27 patients of the
cohort (24%). Twelve patients (10%) were initially diag-
nosed with or suspicious for small distant metastases
(lung in most cases). This was not considered a contra-
indication for a curative loco-regional IMRT approach.
Patients with small or questionable M1 lesions were
included into this analysis, as for those patients the
same difficult question (loco-regionally curative treat-
ment or not?) has to be answered in the clinical routine,
and as suspicion for/limited initial M+ status did not
turn out as an inverse parameter allowing to exclude
patients from loco-regionally curative treatment (see
results).
The selection of patients considered as ‘still potentially
loco-regionally radio-curable’ remains somewhat arbi-
trary and influenced by personal experience, however,
was consistent over the analyzed time period, as all
patients were evaluated by the same radiation oncolo-
gists (CG and GS). Main criteria for the decision to sup-
port a curative treatment approach were 1) the anatomic
tumor extent, including the GTV relation to surround-
ing critical structures, with respect to the boost dose
volume, 2) oral cavity tumors (as definitive radiation of
oral cavity tumors resulting in low disease control [3]),
and 3) taking patients’ compliance and interest in
undergoing a time consuming therapy with risk for tol-
erance problems into account. In patients who pre-
sented with very advanced loco-regional disease with
doubtful curative radio-therapeutic options, induction
chemotherapy (IC) was provided if possible (n = 24).
The aim of the IC was to ease the decision to initiate a
potentially curative versus palliative loco-regional treat-
ment approach, based on the response to IC [4].
- Volumetric staging
In a former evaluation based on 88 retrospectively and
84 prospectively analysed IMRT patients (treated
between 01/2002-12/2004 and 01-11/2005; n = total
172), the volumetric staging system (VSS) was found to
represent the most important predictor for local-regio-
nal outcome [1]. This VSS bases on two cut-offs (15 cc
and 70 cc), resulting in three volumetric subgroups: pri-
mary GTV or total GTV (tGTV) of 1-15 cc (favourable)
vs 16–70 cc (intermediate) vs > 70 cc (unfavourable).
While the primary GTV was used to predict local con-
trol rates, tGTV was shown to best predict nodal con-
trol, distant metastasis free, disease free and overall
survival, respectively. The volumetric criterion has since
Table 1 Characteristics of the analyzed cohort
Parameters Patients
N patients included 112 (100%)
definitive SIB-IMRT 112 (100%)
conc. syst Tx, IC, no syst Tx 75 (70%), 24 (21%), 14 (12%)
time interval 3/2002 - 03/2011
male/female (%) 96/16 (86/14)
age, mean/median (range) 62/61 years (33-87)
WHO performance status 0/1/2 78 (70%)/33 (29%)/1 (1%)
Diagnosis (%)
oropharynx 62 (55%)
hypopharynx 22 (20%)
oral cavity 10 (9%)
larynx 5 (4%)
others 9 (8%)
CUP 4 (4%)
T (number), % recurrence 5, 4% (101 cc, 10-206)
(mean volume, range)
CUP 4, 4% (0 cc)
T1 6, 5% (7 cc, 4-13)
T2 15, 13% (34 cc, 5-63)
T3 23, 20% (60 cc, 10-122)
T4 59, 53% (77 cc, 12-206)
N (number), % recurrence 1, 1% (5 cc)
(mean volume, range)
N0 10, 6% (0 cc)
N1a-2b 39, 13% (34 cc, 1-125)
N2c 37, 64% (30 cc, 1-119)
N3 25, 23% (83 cc, 28-160)
Gross Tumor Volumes (GTV)
mean primary GTV (range) 62 cc (0-206)
mean nodal GTV (range) 41 cc (0-160)
mean total GTV (range) 104 cc (71-251)
Follow up, mean/median (range) months
all patients 26/21 (3-91)
alive patients (n = 58) 30/24 (5-85)
dead patients (n = 39) 18/13 (4-60)
SIB-IMRT: simultaneously integrated boost intensity-modulated radiation
therapy
Conc. CT: concomitant chemotherapy
IC: induction chemotherapy
CUP: carcinoma of unknown primary
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been applied prospectively on our definitive IMRT
patients to estimate disease outcome.
In the current work, we focus on the above described
unfavourable subgroup with tGTV > 70 cc. Additional
volumetric sub-grouping (cut-off 130 cc) and the impact
of systemic therapy were retrospectively tested, aiming
to try to identify a palliative subgroup out of the ‘unfa-
vourable’ cohort with tGTV > 70 cc (outcome data were
first analyzed by retrospectively testing two cut-offs, 100
cc and 130 cc, resulting in nearly identical outcome
results for patients with tGTV 71-100 cc and 101-130
cc, while patients with tGTV > 130 cc did worse; this
finding lead to the retrospective use of one single cut-
off value of 130 cc).
Volumetric three-dimensional measurements (cc) of
contoured GTVs were calculated by the Varian Treat-
ment Planning System (TPS, Eclipse® V8.5, Varian Med-
ical Systems, Palo Alto, CA) volume algorithm.
Methods
- IMRT planning
Patients were immobilized from head to shoulders with
commercially available thermoplastic masks and an indi-
vidually customized bite block. CT images (2 mm slice
thickness) were acquired from the upper aspect of the
orbita to the level of the carina. Contrast agent enhance-
ment was used whenever possible.
The target volumes were drawn on each axial planning
CT slice, based on diagnostic CT images, supplemented
with fused diagnostic MRI and/or PET-CT scans. The
GTV included the gross extent of the primary disease
and involved lymph nodes. PTV1 (planning target
volume) was defined by adding a 1 - 15 mm margin to
the GTV, dependent on the proximity of the lesion to
critical structures. PTV2 covered areas at high risk for
potential microscopic disease. PTV3 included the clini-
cally negative cervical lymphatic nodes down to the
supra-clavicular fossa (elective PTV). Organs at risk were
outlined in three dimensions with an estimated planning
organ-at-risk volume (PRV) margin of 2-10 mm. We
used an extended-field IMRT (EF-IMRT) technique,
where the primary was treated in one phase along with
the regional lymph nodes. Irradiation was delivered with
five or seven coplanar beam angles by a 6-MV dynamic
multi-leaf collimator (MLC) system (sliding-window
technique; Varian Medical Systems, Palo Alto, CA, USA).
In some patients, volumetric modulated arc therapy
(VMAT) technique on a Truebeam® Varian linear accel-
erator was applied. All patients signed an informed con-
sent as approved by our local ethical board.
- Prescription Dose
As previously described [5], SIB-IMRT was performed
using the following schedules (five fractions/week each):
• SIB2.00: daily dose 2.00 Gy (PTV1)/1.70 Gy (PTV2)/
1.54 Gy (PTV3); total dose: 68-70.00 Gy (n = 20);
• SIB2.11: daily dose 2.11 Gy (PTV1)/1.80 Gy (PTV2)/
1.64 Gy (PTV3); total dose: 69.60 -71.7 Gy (n = 76);
• SIB2.20: daily dose 2.20 Gy (PTV1)/2.00 Gy (PTV2)/
1.80 Gy (PTV3); total dose: 66.00 -72.6 Gy (n = 16).
The dose was normalized to the mean dose in PTV1.
For intensity optimization 95% of the prescribed dose
should encompass at least 95% of the PTV and 100% of
the prescribed dose encompassed the GTV. No more
than 20% of any PTV would receive > 110% of its pre-
scribed dose, while no more than 1% of any PTV would
receive < 93% of the desired dose.
If the normal tissue volume or the exposed mucosal
tissue volume was felt to be too large to receive 70 Gy
by using the above described standard PTV1 (GTV plus
1-1.5 cm), the dose to PTV1 was reduced to 66-68 Gy,
with no change to the prescription dose delivered to the
GTV (’GTV-PTV’).
- Chemotherapy
a) Cisplatin
Systemic standard concomitant cisplatin based therapy
was given to eligible patients (n = 76, 68%); our pre-
ferred cisplatin regimen of 40 mg/m2 i. v. per radiation
week was used in all cases.
b) Cetuximab
Since April 2006, cetuximab has been used for patients
who were not eligible to undergo cisplatin chemother-
apy. Most frequent reasons for initial cetuximab therapy
or switch from standard cisplatin based chemotherapy
to cetuximab were decreased hearing, tinnitus, or
impaired renal function (n = 26, 23%). An intravenous
loading dose of 400 mg/m2 cetuximab was administered
in the week prior to the commencement of radiation,
followed by 250 mg/m2 per radiation week.
c) Induction Chemotherapy (IC)
In 24 (21%) compliant patients with no serious medical
contra-indications for IC, who presented with very
advanced loco-regional disease (mean 120 cc, range 73-
177) with poor curability, IC was offered. The aim of IC
was to ease the decision to initiate potentially curative
radiation therapy, based on the response to IC. Most
frequently used IC drug combination was taxotere/cis-
platin/5-fluoro-uracil.
Statistics
The influence of the tumour volume (tGTV) and sys-
temic therapy was retrospectively tested. In addition,
univariate analysis of the impact of TN stages, age, diag-
nosis, distant metastasis at initial diagnosis, and pre-
therapeutic performance status were performed. Statisti-
cal calculations were performed using the statistics pro-
gram implemented in StatView® (version 4.5; SAS
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Institute, Cary, NC). Proportions were compared using
the Chi-square test. Univariate analyses were performed
with a Cox proportional hazards regression model in
StatView®. Actuarial survival data were calculated using
Kaplan-Meier curves and log-rank tests implemented in
StatView®. Stratification of variables was done with help
of log rank (Mantel-Cox) calculation.
P values < 0.05 were considered statistically
significant.
Results
- Disease control
After a mean/median follow up time of 26/21 months, 51
patients (46%) were alive with no evidence of disease
(ANED) when last time seen. The related follow up
times, time to treatment failure and Kaplan Meier actuar-
ial survival curves are shown in Table 2, 3, and Figure 1.
Distant spread (M+) developed in 32/112 patients
(29%); lesions suspicious for M+ were pre-therapeuti-
cally diagnosed in 12/32 patients (38%), which reached
the same 2-year overall survival rate of 65% as the initi-
ally M0-subgroup; 8 of the 12 patients were still alive
mean 11 months post treatment (4-21). In 15/32 (47%),
distant metastases remained the only sign of disease (i.
e., M+ with loco-regional control) mean 21 months (5-
84) post IMRT. In 7 of 32 patients (6% of the entire
cohort) new and isolated distant disease during the
post-treatment follow up period were found.
Thirty-six patients (32%) experienced local failure, in
21 of them (58%), the primary tumour persisted (persis-
tent disease defined as macroscopic persistence or re-
growth to macroscopic disease during the first 3 months
from treatment start). Nodal failure occurred in 25
(22%) patients, in 13/25 (52%) as persistent disease.
- Impact of the tumour volume
The expected inverse association between tumour
volume and disease control was tested using the retro-
spectively chosen cut-off value of 130 cc (Table 3):
tGTV < 130 cc resulted in a tendency towards superior
OAS, DFS and LRC rate, with a significant difference in
the distant metastasis rate.
- Impact of systemic therapy
Patients who where eligible to undergo any systemic
therapy (i. e., 1-7 cycles of concomitant cisplatin or
cetuximab, and/or induction chemotherapy, n = 98
(88%)), versus those who were not (n = 14 (12%) - in
most cases due to co-morbidity and/or age) were found
to achieve significantly superior 3-year survival rates
(Table 3, Figure 2). The tGTV was similar in both
Table 2 Duration of follow up and interval of disease
free survival, analysed according to the status of patients
when last time seen
Status follow up, months time to disease, months
last time seen (n) mean/median (range) mean/median (range)
ANED (51, 46%) 37/36 (3-91) 0
INED (10, 9%) 26/19 (5-60) 0
AD (12, 11%) 10/7 (2-23) 4/8 (0-11)
DOD (39, 35%) 16/12 (4-53) 5/4 (0-28)
ANED: alive with no evidence of disease
INED: inter-current dead without disease
AD: alive with disease
DOD: died of disease
na: not assessable
Table 3 Actuarial survival rates related to +/- systemic
therapy and tGTV volume
Parameters (n) 3y-OAS 3y-DFS 3y-DMFS 3y-LRC
entire cohort (112) 58% 50% 70% 61%
no systemic therapy (14) 25% 17% 50% 25%
any systemic therapy (98) 61% 53% 72% 64%
p-value < 0.0001 0.01 0.1 (NS) 0.04
< 130 cc (91) 58% 51% 75% 62%
> 130 cc (21) 30% 38% 40% 40%
p-value 0.1 (NS) 0.2(NS) 0.001 0.05
no systemic therapy (14) 25% 17% 50% 25%
any systemic therapy, > 130
cc (19)
30% 40% 50% 45%
any systemic therapy, < 130
cc (79)
63% 55% 78% 76%
p-value 0.0001 0.03 0.01 0.04
OAS: overall survival
DMFS: distant metastasis free survival
DFS: disease free survival
LRC: loco-regional control
Figure 1 Kaplan Meier actuarial survival rates of the entire
cohort. LRC: loco-regional control rate. MFS: metastasis free survival
rate. DFS: disease free survival rate. OAS: overall survival.
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groups (mean 99 cc vs 103 cc, NS), while the mean age
expectedly significantly differed (60 years (range 41-81)
in patients with combined modality treatment, vs 73
years (range 58-87) in the IMRT only subgroup, p =
0.01). Eleven of the 14 patients who underwent radiation
only (79%), died from disease during the first 20
months; however, in 8 of them, substantial subjective
loco-regional benefit was documented for a mean dura-
tion of 17 months (range 4-20). The remaining three
patients who experienced no benefit suffered from per-
sistent local disease. Three patients with tGTV > 130 cc
treated with radiation alone died from disease after 2, 3,
and 10 months, respectively.
Only 2/14 (14%) patients treated with IMRT alone
remained alive with no evidence of disease, vs 41/78
(52%) treated with any systemic therapy for tGTV < 130
cc, vs 8/19 (42%) treated for tGTV > 130 cc,
respectively.
- Additional potentially prognostic parameters
The initial pre-treatment WHO performance status
(Table 1) was not found to be of prognostic value (49%
vs 50% 3-year DFS, p = 0.26). Similarly, there was no
gender-related outcome difference (p = 0.3). Analysis
based on T and N stages or TN grouping resulted in
non-significantly different or nearly identical Kaplan
Meier survival curves. Also the primary tumour site
(mesopharynx versus hypopharynx) or age (grouped in
decades: < 50 vs 50-60 vs 61-70 vs > 70 years) showed
no prognostic value. Patients suspicious of distant
metastasis did not worse compared with initially M0-
patients (see above). Any potential impact of the human
papilloma virus (HPV) status on the disease control in
this ‘very large tumour volume’ patient cohort could not
be assessed, as the HPV status was not available in most
of our patients.
Discussion
The previously defined ‘unfavourable’ SCC HNC patient
subgroup with large tGTV > 70 cc [1] has been updated
(Table 1, Figure 1) and further analyzed, using the
advantage of volumetric staging to define further volu-
metric subgroups. The aim of this report was to analyze
whether a subgroup of patients with large tGTV > 70 cc
referred for curative treatment can be defined which
only marginally benefits from intensive curative treat-
ment. Weaknesses of this report are its retrospective
approach, retrospective subgroup analysis, and the use
of different chemotherapeutic schedules and chemother-
apeutic dose-intensity, respectively. The strength of this
report is a homogeneous IMRT contouring and treat-
ment delivery performed according to prospectively
defined treatment schedules in all patients, and in the
relatively large sample size.
Our outcome results are comparable with selected
recently published data on ‘non-resectable’ HNC treated
with radio-chemotherapy, with DFS/OAS rates of
approximately 50/60% versus ~25/45% [6], 65/70% [7],
50/65% [8].
We found a statistically significantly inferior outcome
in patients not being able to undergo any systemic ther-
apy (Table 3 and Figure 2). This result is limited by the
unbalanced sample sizes (14 vs 98), and the significant
difference in mean age (expectedly, as higher age and
related frequent severe co-morbidity are usual reasons
to not apply systemic therapy). It is known that higher
age per se may inversely influence outcome [9] - age
could therefore be an independent reason for inferior
outcome. A potential difference of the impact of sys-
temic therapy on very advanced (’unresectable’) versus
less advanced stages (lower tumor load) HNC is not
well known to our best knowledge. The subgroup with
tGTV > 70 cc and unable to undergo systemic therapy
still achieved 2-year DFS/OAS rates of approximately
30% (Figure 2), justification enough to consider a cura-
tive IMRT approach also for this subgroup.
As in previous investigations on volumetric based out-
come prediction [1] (Table VI in reference [1]) and [2],
an inverse association between tGTV and disease con-
trol was also found in the here assessed patient segment
with ‘very large tumor volume’: patients with tGTV >
130 cc tended towards inferior outcome, with nearly
40% achieving 3-year disease control (versus > 50% in
patients with tGTV < 130 cc (NS), Table 3); again, this
outcome data justify offering a curative combined mod-
ality treatment to compliant patients with very large
tumor volumes.
Eight of 12 patients suspicious of initial M+ status
were still alive at mean ~1 year (range 4-21 months)
post treatment, enjoying beneficial treatment effects; the
imaging diagnosis of limited M+ status should not be
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Figure 2 Kaplan-Meier actuarial disease free survival (DFS)
rates of subgroups with and without any systemic therapy.
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used as a criterion to exclude patients from loco-regio-
nal curative IMRT approach. Radiation is known as
most effective local therapy for advanced non-resectable
loco-regional disease, however requiring high doses, if
possible enhanced by systemic therapy. In order to keep
side effects as low as possible, IMRT should be used
also in patients with radiologically suspicious distant
lesions. Whether further investigation should be per-
formed on suspicious M1 lesions has to be decided case
by case.
The most unfavourable subgroup seems characterized
by (elderly) patients with a tumour load of > 130 cc and
unable to undergo any systemic treatment - this group
however was too small to draw reliable conclusions
from it (this question is under prospective evaluation at
our institution).
In sum
• patients with tGTV > 70 cc treated with IMRT and
systemic therapy achieved 3-year DFS and OAS of
approximately 50% and 60%, respectively
• (elderly) patients with tGTV > 70 cc treated with
IMRT alone represented a subgroup which only margin-
ally benefits from curative IMRT (3-year OAS/DFS
~25%/< 20%, 3-year DFS 17%); nevertheless, most
patients experienced subjective benefit from radiation in
terms of symptom relief, which is considered justifying
IMRT at least aiming effective palliation
• (elderly) patients with very large tGTV > 130 cc
treated with IMRT alone did worst (1-y OAS 0%), how-
ever, a larger sample size is needed for corroboration
Conclusions
Tumour volume and eligibility to undergo systemic
therapy were found important prognostic factors in
patients with large tGTV load > 70 cc.
Larger sample sizes are required to test, if patients
with tGTV > 130 cc and unable to undergo systemic
therapy should be prevented from curative treatment
approaches.
Radiobiological parameters may identify other criteria
to define a palliative subgroup among the patients with
very large tumour volumes.
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